{"id":7896,"date":"2025-10-31T17:07:18","date_gmt":"2025-11-01T00:07:18","guid":{"rendered":"https:\/\/highfieldbio.com\/?p=7896"},"modified":"2025-12-04T06:09:21","modified_gmt":"2025-12-04T14:09:21","slug":"clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth","status":"publish","type":"post","link":"https:\/\/highfieldbio.com\/zh\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/","title":{"rendered":"HighField Biopharmaceuticals \u7684\u4e24\u6b3e\u514d\u75ab\u80bf\u7624\u8102\u8d28\u7597\u6cd5\u7684\u4e34\u5e8a\u6570\u636e\u88ab\u63a5\u53d7\u4e3a\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) \u7b2c 40 \u5c4a\u5e74\u4f1a\uff082025 \u5e74 11 \u6708 5 \u65e5\u81f3 9 \u65e5\uff09\u7684\u6700\u65b0\u6458\u8981\u62a5\u544a\u3002"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"7896\" class=\"elementor elementor-7896\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7c3df96 elementor-section-boxed elementor-section-height-default elementor-section-height-default smart-sticky-default\" data-id=\"7c3df96\" data-element_type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f09d554\" data-id=\"f09d554\" data-element_type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-33706a9 elementor-widget elementor-widget-spacer\" data-id=\"33706a9\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7f9ed22 elementor-widget elementor-widget-udesign_widget_heading\" data-id=\"7f9ed22\" data-element_type=\"widget\" data-widget_type=\"udesign_widget_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"title-wrapper  title-cross title-center\"><p class=\"title elementor-heading-title\">2025\u5e7410\u670831\u65e5 | HighField Bio\u65b0\u95fb\u7a3f<\/p><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b2ac3db elementor-widget elementor-widget-spacer\" data-id=\"b2ac3db\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ac618a2 elementor-widget elementor-widget-udesign_widget_heading\" data-id=\"ac618a2\" data-element_type=\"widget\" data-widget_type=\"udesign_widget_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"title-wrapper  title-center\"><h2 class=\"title elementor-heading-title\">HighField Biopharmaceuticals \u7684\u4e24\u6b3e\u514d\u75ab\u80bf\u7624\u8102\u8d28\u7597\u6cd5\u7684\u4e34\u5e8a\u6570\u636e\u88ab\u63a5\u53d7\u4e3a\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) \u7b2c 40 \u5c4a\u5e74\u4f1a\uff082025 \u5e74 11 \u6708 5 \u65e5\u81f3 9 \u65e5\uff09\u7684\u6700\u65b0\u6458\u8981\u62a5\u544a\u3002<\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-027104d alpha-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-height-default smart-sticky-default\" data-id=\"027104d\" data-element_type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-a846582\" data-id=\"a846582\" data-element_type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ed689c6 elementor-widget elementor-widget-text-editor\" data-id=\"ed689c6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><h4>\u6458\u8981 <em>\u201c<\/em><em>HF50\u662f\u4e00\u79cd\u65b0\u578b\u8102\u8d28\u4f53HER2xCD3 T\u7ec6\u80de\u8854\u63a5\u5668\uff0c\u5e26\u6709TLR\u6fc0\u52a8\u5242\u6709\u6548\u8f7d\u8377\uff0c\u9996\u6b21\u4eba\u4f53\u8bc4\u4f30\u663e\u793a\u5176\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u548c\u65e9\u671f\u4e34\u5e8a\u7597\u6548\u3002<\/em> \u62ab\u9732\u4e86HighField\u5728\u514d\u75ab\u7597\u6cd5\u4e2d\u91c7\u7528\u7684\u591a\u65b9\u9762\u65b9\u6cd5\u7684\u65b0\u6570\u636e\u3002<\/h4><\/li><li style=\"text-align: center;\"><h4>\u6458\u8981 <em>\u201c\u5229\u7528 HF1K16 \u9776\u5411 MDSC \u53ef\u5ef6\u957f\u96be\u6cbb\u6027\u590d\u53d1\u6027\u80f6\u8d28\u7624\u60a3\u8005\u7684\u751f\u5b58\u671f\uff1bNCT05388487 \u7684\u6700\u65b0\u7814\u7a76\u8fdb\u5c55\u201d<\/em> \u8fd9\u4f53\u73b0\u4e86 HighField \u5f00\u53d1\u80fd\u591f\u63d0\u9ad8\u6574\u4f53\u751f\u5b58\u7387\u7684\u4ea7\u54c1\u7684\u613f\u666f\u3002<\/h4><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e59da4e elementor-widget-laptop__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e59da4e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>\u4e2d\u56fd\u676d\u5dde\uff082025\u5e7410\u670831\u65e5\uff09\u2014\u2014\u4e13\u6ce8\u4e8e\u5229\u7528\u8102\u8d28\u7597\u6cd5\u6cbb\u7597\u764c\u75c7\u53ca\u5176\u4ed6\u75be\u75c5\u7684\u4e34\u5e8a\u9636\u6bb5\u751f\u7269\u5236\u836f\u516c\u53f8HighField Biopharmaceuticals\u4eca\u65e5\u5ba3\u5e03\uff0c\u5c06\u5728\u4e16\u754c\u751f\u7269\u5236\u836f\u5927\u4f1a\u4e0a\u5c31\u5176\u4e24\u6b3e\u65b0\u578b\u514d\u75ab\u80bf\u7624\u836f\u7269\u8fdb\u884c\u6700\u65b0\u7814\u7a76\u6210\u679c\u6458\u8981\u62a5\u544a\u3002 <a href=\"https:\/\/www.sitcancer.org\/2025\/home\">\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a (SITC) 40<sup>\u65e5<\/sup> \u5468\u5e74\u7eaa\u5ff5\u4f1a\u8bae<\/a> 2025\u5e7411\u67085\u65e5\u81f39\u65e5\uff0c\u9a6c\u91cc\u5170\u5dde\u56fd\u5bb6\u6e2f\u3002<\/p><p>\u201c\u6211\u4eec\u975e\u5e38\u6b23\u6170SITC\u8ba4\u53ef\u4e86\u6211\u4eec\u5f00\u53d1\u4e0b\u4e00\u4ee3\u514d\u75ab\u7597\u6cd5\u7684\u52aa\u529b\uff0c\u201dHighField\u9996\u5e2d\u6267\u884c\u5b98\u517c\u79d1\u5b66\u521b\u59cb\u4eba\u5f90\u5b87\u7ea2\u8868\u793a\uff0c\u201c\u6211\u4eec\u6b63\u5f15\u9886\u7740\u57fa\u4e8e\u8102\u8d28\u7684\u4ea7\u54c1\u7684\u7814\u53d1\uff0c\u8fd9\u4e9b\u4ea7\u54c1\u4e13\u6ce8\u4e8e\u80bf\u7624\u5fae\u73af\u5883\u4e2dT\u7ec6\u80de\u8c03\u63a7\u7684\u4e0d\u540c\u65b9\u9762\u3002\u201d<\/p><p>\u5f90\u535a\u58eb\u89e3\u91ca\u8bf4\uff1a\u201cHF1K16 \u548c HF50 \u662f\u6211\u4eec\u57fa\u4e8e\u8102\u8d28\u6cbb\u7597\u5e73\u53f0\u7684\u4e00\u7cfb\u5217\u4ea7\u54c1\u7684\u4e00\u90e8\u5206\u3002\u5b83\u4eec\u4ee3\u8868\u4e86\u764c\u75c7\u514d\u75ab\u7597\u6cd5\u6cbb\u7597\u7684\u65b0\u613f\u666f\uff0c\u65e8\u5728\u4e3a\u66f4\u591a\u60a3\u8005\u5e26\u6765\u66f4\u597d\u7684\u6cbb\u7597\u6548\u679c\u3002\u8be5\u7cfb\u5217\u4ea7\u54c1\u8fd8\u5305\u62ec\u57fa\u4e8e\u6211\u4eec TCTplex T \u7ec6\u80de\u57fa\u56e0\u7f16\u8f91\u5e73\u53f0\u7684 HFG2\uff0c\u7528\u4e8e\u521b\u5efa <em>\u4f53\u5185<\/em> CAR-T\u7ec6\u80de\u3002\u201d<\/p><p>\u6458\u8981 <em>\u6570\u5b57<\/em> <em>1314<\/em>\u6807\u9898\u4e3a <a href=\"https:\/\/www.sitcancer.org\/2025\/abstracts\/titles-and-publications?SITC%202025%20Abstracts%5Bquery%5D=First-in-human%20evaluation%20of%20HF50\"><strong>HF50\u662f\u4e00\u79cd\u65b0\u578b\u8102\u8d28\u4f53HER2xCD3 T\u7ec6\u80de\u8854\u63a5\u5668\uff0c\u643a\u5e26TLR\u6fc0\u52a8\u5242\u6709\u6548\u8f7d\u8377\uff0c\u9996\u6b21\u4eba\u4f53\u8bc4\u4f30\u663e\u793a\u5176\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u548c\u65e9\u671f\u4e34\u5e8a\u7597\u6548\u3002<\/strong><\/a>\u5c06\u4e8e11\u67088\u65e5\u661f\u671f\u516d\u4e3e\u884c\u3002<\/p><p>\u6458\u8981 <em>\u7b2c1350\u53f7<\/em>\u6807\u9898\u4e3a <a href=\"https:\/\/www.sitcancer.org\/2025\/abstracts\/titles-and-publications?SITC%202025%20Abstracts%5Bquery%5D=Targeting%20MDSCs%20with%20HF1K16%20\"><strong>\u5229\u7528 HF1K16 \u9776\u5411 MDSC \u53ef\u5ef6\u957f\u96be\u6cbb\u6027\u590d\u53d1\u6027\u80f6\u8d28\u7624\u60a3\u8005\u7684\u751f\u5b58\u671f\uff1bNCT05388487 \u7684\u6700\u65b0\u7814\u7a76\u8fdb\u5c55<\/strong><\/a>\u5c06\u4e8e11\u67088\u65e5\u661f\u671f\u516d\u4e3e\u884c\u3002<\/p><p><strong>\u5173\u4e8e HighField \u751f\u7269\u5236\u836f<\/strong><\/p><p>Highfield \u662f\u4e00\u5bb6\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8\uff0c\u4e13\u6ce8\u4e8e\u9488\u5bf9\u514d\u75ab\u80bf\u7624\u5b66\u548c\u57fa\u56e0\u6cbb\u7597\u7684\u8102\u8d28\u4f53\u7ed3\u6784\u7684\u65b0\u5e94\u7528\u3002HighField \u5728\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u4e3b\u5bfc\u4ea7\u54c1\u662f K1\uff0c\u6e90\u81ea\u5176 ADCplex<sup>\u5546\u6807<\/sup> \u5e73\u53f0\uff0c\u968f\u540e\u662f HF50\uff0c\u6e90\u81ea\u5176 TCEplex<sup>\u5546\u6807 <\/sup>\u5e73\u53f0\u3002\u8be5\u516c\u53f8\u7684\u4ea7\u54c1\u7ebf\u8fd8\u5305\u62ec K16\uff0c\u4e00\u79cd\u836f\u7269\u5305\u88f9\u7684\u514d\u75ab\u8c03\u8282\u8102\u8d28\u4f53\uff0c\u9776\u5411\u9aa8\u9ad3\u6765\u6e90\u7684\u6291\u5236\u7ec6\u80de\uff0c\u7528\u4e8e\u96be\u6cbb\u6027\u764c\u75c7\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff1b\u4ee5\u53ca\u6e90\u81ea\u5176 tLNPplex\u2122 \u5e73\u53f0\u7684 HFG1\uff0c\u7528\u4e8e GLP-1R \u6fc0\u52a8\u5242\u7684 mRNA \u8868\u8fbe\uff0c\u7528\u4e8e\u51cf\u80a5\u548c\u6cbb\u7597\u7cd6\u5c3f\u75c5\u3002\u6709\u5173\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee <a href=\"https:\/\/highfieldbio.com\/zh\">highfieldbio.com<\/a>.<\/p><p>\u5a92\u4f53\u8054\u7cfb\u65b9\u5f0f\uff1a<\/p><p>\u4e39\u00b7\u57c3\u62c9\u7c73\u5b89<\/p><p>Opus \u751f\u7269\u6280\u672f\u901a\u8baf<\/p><p><a href=\"mailto:danieleramian@comcast.net\">danieleramian@comcast.net<\/a><\/p><p>425-306-8716<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>HighField Biopharmaceuticals\u516c\u53f8\u4e24\u6b3e\u514d\u75ab\u80bf\u7624\u8102\u8d28\u4f53\u7597\u6cd5\u7684\u4e34\u5e8a\u6570\u636e\u5df2\u88ab2025\u5e7411\u67085\u65e5\u81f39\u65e5\u4e3e\u884c\u7684\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a\uff08SITC\uff09\u7b2c40\u5c4a\u5e74\u4f1a\u63a5\u6536\uff0c\u5c06\u4ee5\u6700\u65b0\u7814\u7a76\u6458\u8981\u7684\u5f62\u5f0f\u8fdb\u884c\u62a5\u544a\u3002\u6458\u8981\u6807\u9898\u4e3a\u201cHF50\uff08\u4e00\u79cd\u65b0\u578b\u8102\u8d28\u4f53HER2xCD3 T\u7ec6\u80de\u8854\u63a5\u5242\uff0c\u8d1f\u8f7dTLR\u6fc0\u52a8\u5242\uff09\u7684\u9996\u6b21\u4eba\u4f53\u8bc4\u4f30\u663e\u793a\u5176\u5177\u6709\u826f\u597d\u7684\u8010\u53d7\u6027\u548c\u65e9\u671f\u4e34\u5e8a\u7597\u6548\u201d[\u2026]<\/p>","protected":false},"author":2,"featured_media":7606,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[22],"tags":[],"class_list":["post-7896","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025. - HighField Biopharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/highfieldbio.com\/zh\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025. - HighField Biopharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025. The abstract \u201cFirst-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demonstrates Tolerability and Early Clinical Response\u201d [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/highfieldbio.com\/zh\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/\" \/>\n<meta property=\"og:site_name\" content=\"HighField Biopharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-01T00:07:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-04T14:09:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"HighField Bio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/\"},\"author\":{\"name\":\"HighField Bio\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/b757079db9e1fda8b0377dd359a99475\"},\"headline\":\"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025.\",\"datePublished\":\"2025-11-01T00:07:18+00:00\",\"dateModified\":\"2025-12-04T14:09:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/\"},\"wordCount\":439,\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"articleSection\":[\"Press Release\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/\",\"url\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/\",\"name\":\"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025. - HighField Biopharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"datePublished\":\"2025-11-01T00:07:18+00:00\",\"dateModified\":\"2025-12-04T14:09:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#primaryimage\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/highfieldbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/highfieldbio.com\/#website\",\"url\":\"https:\/\/highfieldbio.com\/\",\"name\":\"HighField Bio\",\"description\":\"Lipid-based Therapeutics Targeting the Tumor Microenvironment\",\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"alternateName\":\"HighField Biopharmaceuticals\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/highfieldbio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/highfieldbio.com\/#organization\",\"name\":\"HighField Biopharmaceuticals, Inc.\",\"alternateName\":\"HighField Bio\",\"url\":\"https:\/\/highfieldbio.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"width\":1500,\"height\":494,\"caption\":\"HighField Biopharmaceuticals, Inc.\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/highfield-biopharma\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/b757079db9e1fda8b0377dd359a99475\",\"name\":\"HighField Bio\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6e842e4864e930156a232f5898a31461e8e42e877bd72fbdf53541c1f5a8e98a?s=80&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6e842e4864e930156a232f5898a31461e8e42e877bd72fbdf53541c1f5a8e98a?s=80&d=mm&r=g\",\"caption\":\"HighField Bio\"},\"sameAs\":[\"https:\/\/highfieldbio.com\"],\"url\":\"https:\/\/highfieldbio.com\/zh\/author\/highfield-bio\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HighField Biopharmaceuticals\u516c\u53f8\u4e24\u6b3e\u57fa\u4e8e\u8102\u8d28\u4f53\u7684\u514d\u75ab\u80bf\u7624\u7597\u6cd5\u7684\u4e34\u5e8a\u6570\u636e\u5df2\u88ab2025\u5e7411\u67085\u65e5\u81f39\u65e5\u4e3e\u884c\u7684\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a\uff08SITC\uff09\u7b2c40\u5c4a\u5e74\u4f1a\u63a5\u6536\uff0c\u5c06\u4ee5\u6700\u65b0\u7814\u7a76\u6210\u679c\u6458\u8981\u7684\u5f62\u5f0f\u8fdb\u884c\u62a5\u544a\u3002\u2014\u2014HighField Biopharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/highfieldbio.com\/zh\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/","og_locale":"zh_CN","og_type":"article","og_title":"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025. - HighField Biopharmaceuticals","og_description":"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025. The abstract \u201cFirst-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demonstrates Tolerability and Early Clinical Response\u201d [&hellip;]","og_url":"https:\/\/highfieldbio.com\/zh\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/","og_site_name":"HighField Biopharmaceuticals","article_published_time":"2025-11-01T00:07:18+00:00","article_modified_time":"2025-12-04T14:09:21+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","type":"image\/jpeg"}],"author":"HighField Bio","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#article","isPartOf":{"@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/"},"author":{"name":"HighField Bio","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/b757079db9e1fda8b0377dd359a99475"},"headline":"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025.","datePublished":"2025-11-01T00:07:18+00:00","dateModified":"2025-12-04T14:09:21+00:00","mainEntityOfPage":{"@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/"},"wordCount":439,"publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"image":{"@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","articleSection":["Press Release"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/","url":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/","name":"HighField Biopharmaceuticals\u516c\u53f8\u4e24\u6b3e\u57fa\u4e8e\u8102\u8d28\u4f53\u7684\u514d\u75ab\u80bf\u7624\u7597\u6cd5\u7684\u4e34\u5e8a\u6570\u636e\u5df2\u88ab2025\u5e7411\u67085\u65e5\u81f39\u65e5\u4e3e\u884c\u7684\u764c\u75c7\u514d\u75ab\u6cbb\u7597\u5b66\u4f1a\uff08SITC\uff09\u7b2c40\u5c4a\u5e74\u4f1a\u63a5\u6536\uff0c\u5c06\u4ee5\u6700\u65b0\u7814\u7a76\u6210\u679c\u6458\u8981\u7684\u5f62\u5f0f\u8fdb\u884c\u62a5\u544a\u3002\u2014\u2014HighField Biopharmaceuticals","isPartOf":{"@id":"https:\/\/highfieldbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#primaryimage"},"image":{"@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","datePublished":"2025-11-01T00:07:18+00:00","dateModified":"2025-12-04T14:09:21+00:00","breadcrumb":{"@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#primaryimage","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/highfieldbio.com\/2025\/10\/31\/clinical-data-of-two-highfield-biopharmaceuticals-immuno-oncology-lipid-based-therapeutics-accepted-for-late-breaking-abstract-presentations-at-the-40th-anniversary-meeting-of-the-society-for-immunoth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/highfieldbio.com\/"},{"@type":"ListItem","position":2,"name":"Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 \u2013 9, 2025."}]},{"@type":"WebSite","@id":"https:\/\/highfieldbio.com\/#website","url":"https:\/\/highfieldbio.com\/","name":"\u9ad8\u7530\u751f\u7269","description":"\u9488\u5bf9\u80bf\u7624\u5fae\u73af\u5883\u7684\u8102\u8d28\u7597\u6cd5","publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"alternateName":"HighField Biopharmaceuticals","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/highfieldbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/highfieldbio.com\/#organization","name":"\u6d77\u83f2\u5c14\u5fb7\u751f\u7269\u5236\u836f\u6709\u9650\u516c\u53f8","alternateName":"HighField Bio","url":"https:\/\/highfieldbio.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","width":1500,"height":494,"caption":"HighField Biopharmaceuticals, Inc."},"image":{"@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/highfield-biopharma"]},{"@type":"Person","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/b757079db9e1fda8b0377dd359a99475","name":"\u9ad8\u7530\u751f\u7269","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6e842e4864e930156a232f5898a31461e8e42e877bd72fbdf53541c1f5a8e98a?s=80&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6e842e4864e930156a232f5898a31461e8e42e877bd72fbdf53541c1f5a8e98a?s=80&d=mm&r=g","caption":"HighField Bio"},"sameAs":["https:\/\/highfieldbio.com"],"url":"https:\/\/highfieldbio.com\/zh\/author\/highfield-bio\/"}]}},"_links":{"self":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/comments?post=7896"}],"version-history":[{"count":7,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7896\/revisions"}],"predecessor-version":[{"id":7904,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7896\/revisions\/7904"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media\/7606"}],"wp:attachment":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media?parent=7896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/categories?post=7896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/tags?post=7896"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}